Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
Zymeworks (Nasdaq: ZYME) will report third quarter 2025 financial results after market close on November 6, 2025. Management will host a conference call and live webcast the same day at 4:30 pm Eastern Time to discuss results and provide a corporate update.
Dial-in details and webcast replays will be available on Zymeworks’ investor website at https://ir.zymeworks.com/events-and-presentations.
Zymeworks (Nasdaq: ZYME) riporterà i risultati finanziari del terzo trimestre 2025 dopo la chiusura del mercato il 6 novembre 2025. Il management terrà una conference call e una diretta webcast nello stesso giorno alle 16:30 ora orientale per discutere i risultati e fornire un aggiornamento aziendale.
Dettagli per la dial-in e le repliche webcast saranno disponibili sul sito investitori di Zymeworks all'indirizzo https://ir.zymeworks.com/events-and-presentations.
Zymeworks (Nasdaq: ZYME) informará los resultados financieros del tercer trimestre de 2025 tras el cierre del mercado el 6 de noviembre de 2025. La dirección organizará una conferencia telefónica y webcast en vivo el mismo día a las 4:30 p.m. hora del Este para discutir los resultados y proporcionar una actualización corporativa.
Los datos de marcación y las repeticiones del webcast estarán disponibles en el sitio web de inversores de Zymeworks en https://ir.zymeworks.com/events-and-presentations.
Zymeworks (나스닥: ZYME)는 2025년 3분기 재무 실적을 2025년 11월 6일 장 마감 후 발표합니다. 경영진은 같은 날 동부 표준시 기준 오후 4시 30분에 컨퍼런스 콜과 라이브 웹캐스트를 개최하여 실적을 논의하고 기업 업데이트를 제공합니다.
다이얼인 정보와 웹캐스트 재방송은 Zymeworks 투자자 웹사이트 https://ir.zymeworks.com/events-and-presentations에서 확인할 수 있습니다.
Zymeworks (Nasdaq : ZYME) annoncera les résultats financiers du troisième trimestre 2025 après la clôture du marché le 6 novembre 2025. La direction organisera une conférence téléphonique et une diffusion en direct le même jour à 16 h 30, heure de l'Est pour discuter des résultats et fournir une mise à jour de l'entreprise.
Les détails pour le dial-in et les rediffusions seront disponibles sur le site investisseurs de Zymeworks à l'adresse https://ir.zymeworks.com/events-and-presentations.
Zymeworks (Nasdaq: ZYME) wird die Finanzergebnisse für das dritte Quartal 2025 nach Börsenschluss am 6. November 2025 melden. Das Management wird am selben Tag um 16:30 Uhr Ostzeit eine Telefonkonferenz und einen Live-Webcast durchführen, um Ergebnisse zu besprechen und ein Unternehmensupdate zu geben.
Dial-In-Details und Webcast-Wiederholungen sind auf der Investorenseite von Zymeworks unter https://ir.zymeworks.com/events-and-presentations erhältlich.
Zymeworks (ناسداك: ZYME) ستعلن عن نتائجها المالية للربع الثالث من عام 2025 بعد إغلاق السوق في 6 نوفمبر 2025. ستعقد الإدارة مكالمة جماعية وبثاً مباشراً عبر الويب في نفس اليوم في الساعة 4:30 مساءً بتوقيت شرق الولايات المتحدة لمناقشة النتائج وتقديم تحديث مؤسسي.
سيتم توفير تفاصيل الاتصال والهاتف وإعادة تشغيل البث عبر موقع المستثمرين لشركة Zymeworks على العنوان https://ir.zymeworks.com/events-and-presentations.
Zymeworks (纳斯达克：ZYME) 将在市场收盘后披露 2025 年第三季度 财务业绩，时间为 2025 年 11 月 6 日。管理层将同日举行电话会议并进行现场网络广播，时间为 美国东部时间下午 4:30，以讨论业绩并提供公司更新。
拨入信息和网络广播的回放将于 Zymeworks 投资者网站 https://ir.zymeworks.com/events-and-presentations 上提供。
- None.
- None.
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its third quarter 2025 financial results after market close on November 6, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on November 6, 2025 at 4:30 pm Eastern Time (ET).
The event will be webcast live with dial-in details and webcast replays available on Zymeworks’ website at https://ir.zymeworks.com/events-and-presentations.
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab has received accelerated approval from the U.S. FDA, conditional approval from the NMPA in China, and conditional marketing authorization from the European Commission for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. It is the first and only dual HER2-targeted bispecific antibody approved for this indication in the U.S., Europe, and China. Zanidatamab is also being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. A Phase 1 study for ZW191 is actively recruiting and ZW251 is expected to enter clinical trials in 2025. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
FAQ
When will Zymeworks (ZYME) report Q3 2025 results?
What time is the Zymeworks (ZYME) conference call and webcast on November 6, 2025?
Where can I access the Zymeworks (ZYME) webcast and replay for the Q3 2025 results?
Who will present Zymeworks (ZYME) Q3 2025 results on the conference call?
Will Zymeworks (ZYME) provide dial-in details for the November 6, 2025 call?
